Barclays raised the firm’s price target on Argenx (ARGX) to EUR 670 from EUR 650 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $706 from $675 at Evercore ISI
- Argenx price target raised to $675 from $646 at Oppenheimer
- Argenx may have first targeted myositis treatment, says H.C. Wainwright
- Argenx SE Boosts Myositis Treatment Development
- Argenx to continue development of efgartigimod subcutaneous